China challenged America's dominance in manufacturing, technology and artificial intelligence. Now, it is threatening another American stronghold: the pharmaceutical industry.

Chinese biotech companies are developing breakthrough drugs faster and cheaper than their American counterparts. One Chinese cancer drug, ivonescimab, is emerging as a potential challenger to Keytruda, Merck's $31-billion blockbuster. Meanwhile, Western pharmaceutical giants are striking multibillion-dollar licensing deals with Chinese innovators.

But Washington is worried. Could America's growing dependence on Chinese biotechnology become a national security threat? And could India benefit from this escalating rivalry?

In this episode of The Morning Brief Decode, Anirban Chowdhury speaks to The Economic Times' pharma editor Vikas Dandekar about China's biotech revolution, the battle for the future of medicine, the US response and India's opportunity to become a bigger player in global drug innovation.

See omnystudio.com/listener for privacy information.

India’s smartphone market is heading into Diwali on a sour note. Shipments fell sharply in the July–September quarter, with the sub-₹20,000 segment hit hardest. A global memory-chip crunch is raising costs, pushing up prices and forcing buyers to delay upgrades, settle for fewer features or choose refurbished phones. But does this slump signal a wider squeeze on household spending, or is it a supply shock tied to the race to build AI data centres? We examine what falling shipments reveal about affordability, consumption and India’s mobile growth, with Counterpoint Research’s Tarun Pathak and Bank of Baroda chief economist Madan Sabnavis.

See omnystudio.com/listener for privacy information.

What if you didn’t need a tech team, or any code, to build software?
In this episode of Corner Office Conversation, Anirban Chowdhury sits down with Mukund Jha, Founder and CEO of Emergent, the AI platform where anyone with an idea can build a real, hosted, working app. A former Google engineer, Mukund also co-founded Dunzo, the unicorn that became a verb in India...and then folded.
He shares hard-won Dunzo lessons on growth versus endurance, focus and unit economics, and why second-mover advantage matters in AI. Emergent says 18 million apps have been built on it. Mukund believes anyone could soon build any software without code.

See omnystudio.com/listener for privacy information.